Abstract
The dopaminergic stabilizer pridopidine demonstrates state-dependent effects on locomotor activity, counteracting both hypo- and hyperactivity in rats. Pridopidine has been shown to display both functional dopamine D2 receptor antagonist properties and increase in biomarkers associated with NMDA-mediated glutamate transmission in the frontal cortex. To further characterise the effects of pridopidine on prefrontal cortex (PFC) neurons, a series of in vivo electrophysiological studies were performed in urethane-anaesthetised rats. Pridopidine, administered at doses from 10 to 60 mg/kg (i.v.), dose dependently increased pyramidal cell firing in the majority of the neurons tested. Pridopidine induced a significant increase of 162 % in mean firing activity of PFC neurons, versus initial basal firing activity as the cumulative dose of 30 mg/kg, i.v., was administered. This enhancement of activity was due to increased firing frequency of already spontaneously active neurons, rather than an increase in population activity. The increase was partially reversed or prevented by a sub-threshold dose of the dopamine D1 receptor antagonist SCH23390 (0.5 mg/kg, i.v.). Microiontophoretic application of pridopidine had only moderate activating effects. The selective dopamine D1 receptor agonist A-68930 also had limited effects when administered by microiontophoretic application, but exerted a dose dependent (0.2–3 mg/kg, i.v.) activation of firing in the majority of neurons tested (10/16). However, inhibition of firing by systemic administration of A-68930 was also observed in a subgroup of neurons (6/16). Both activation and inhibition of firing induced by systemic administration of A-68930 were reversed by the systemic administration of SCH23390. The present data suggests that pridopidine enhances pyramidal cell firing via an indirect dopamine D1 receptor-mediated mechanism. These effects of pridopidine may serve to strengthen the cortico-striatal communication and to improve motor control in Huntington’s disease for which pridopidine is currently in development.
Similar content being viewed by others
References
Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381
Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathe JM, Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedebergs Arch Pharmacol 352:374–385
Bramham CR, Alme MN, Bittins M, Kuipers SD, Nair RR, Pai B, Panja D, Schubert M, Soule J, Tiron A, Wibrand K (2010) The arc of synaptic memory. Exp Brain Res 200:125–140
Cools R (2011) Dopaminergic control of the striatum for high-level cognition. Curr Opin Neurobiol 21:402–407
Creese I, Burt DR, Snyder SH (1996) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. J Neuropsychiatry Clin Neurosci 8:223–226
Dallerac GM, Vatsavayai SC, Cummings DM, Milnerwood AJ, Peddie CJ, Evans KA, Walters SW, Rezaie P, Hirst MC, Murphy KP (2011) Impaired long-term potentiation in the prefrontal cortex of Huntington’s disease mouse models: rescue by D1 dopamine receptor activation. Neurodegener Dis 8:230–239
de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J (2011) Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:1049–1057
Devoto P, Flore G (2006) On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons? Curr Neuropharmacol 4:115–125
Dyhring T, Nielsen EO, Sonesson C, Pettersson F, Karlsson J, Svensson P, Christophersen P, Waters N (2010) The dopaminergic stabilizers pridopidine (ACR16) and (−)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 628:19–26
Easton N, Steward C, Marshall F, Fone K, Marsden C (2007) Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 52:405–414
Eltayb A, Wadenberg ML, Svensson TH (2005) Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose l-dopa. Biol Psychiatry 58:337–343
Glausier JR, Khan ZU, Muly EC (2009) Dopamine D1 and D5 receptors are localized to discrete populations of interneurons in primate prefrontal cortex. Cereb Cortex 19:1820–1834
Gronier B (2011) In vivo electrophysiological effects of methylphenidate in the prefrontal cortex: involvement of dopamine D1 and alpha 2 adrenergic receptors. Eur Neuropsychopharmacol 21:192–204
Gronier B, Debonnel G (1999) Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur J Pharmacol 368:183–196
Gronier B, Aston J, Liauzun C, Zetterstrom T (2009) Age-dependent effects of methylphenidate in the prefrontal cortex: evidence from electrophysiological and Arc gene expression measurements. J Psychopharmacol 24:1819–1827
Gudelsky GA (1995) Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur J Pharmacol 286:223–228
Gui ZH, Zhang QJ, Liu J, Ali U, Li LB, Wang Y, Wang T, Chen L, Hou C, Fan LL (2010) In vivo modulation of the firing activity of putative slow- and fast-spiking interneurons in the medial prefrontal cortex by 5-HT3 receptors in 6-hydroxydopamine-induced Parkinsonian rats. Neuroscience 169:1315–1325
Hajos M, Gartside SE, Varga V, Sharp T (2003) In vivo inhibition of neuronal activity in the rat ventromedial prefrontal cortex by midbrain-raphe nuclei: role of 5-HT1A receptors. Neuropharmacology 45:72–81
Hohn S, Dallerac G, Faure A, Urbach YK, Nguyen HP, Riess O, von Horsten S, Le Blanc P, Desvignes N, El Massioui N, Brown BL, Doyere V (2011) Behavioral and in vivo electrophysiological evidence for presymptomatic alteration of prefrontostriatal processing in the transgenic rat model for Huntington disease. J Neurosci 31:8986–8997
Homayoun H, Moghaddam B (2006) Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb Cortex 16:93–105
Hu XT, Wang RY (1988) Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study. J Neurosci 8:4340–4348
Ichikawa J, Meltzer HY (1999) R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(−)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291:1227–1232
Isacson R, Kull B, Wahlestedt C, Salmi P (2004) A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex? Neuroscience 124:33–42
Kargieman L, Santana N, Mengod G, Celada P, Artigas F (2008) NMDA antagonist and antipsychotic actions in cortico-subcortical circuits. Neurotox Res 14:129–140
Kawashima T, Okuno H, Nonaka M, Adachi-Morishima A, Kyo N, Okamura M, Takemoto-Kimura S, Worley PF, Bito H (2009) Synaptic activity-responsive element in the Arc/Arg3.1 promoter essential for synapse-to-nucleus signalling in activated neurons. Proc Natl Acad Sci USA 106:316–321
Kieburtz K, On behalf of the HSG HART study investigators (2011) A randomized, double-blind, placebo-controlled trial of ACR16 in Huntington’s disease Neurotherapeutics, p 135
Kritzer MF, Goldman-Rakic PS (1995) Intrinsic circuit organization of the major layers and sublayers of the dorsolateral prefrontal cortex in the rhesus monkey. J Comp Neurol 359:131–143
Kruse MS, Premont J, Krebs MO, Jay TM (2009) Interaction of dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex. Eur Neuropsychopharmacol 19:296–304
Labonte B, Bambico FR, Gobbi G (2009) Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 380:383–397
Landwehrmeyer B, Marder K, Biilmann Rønn B, Haglund M, On behalf of the MermaiHD and HART study investigators (2011) Effect of the dopaminergic stabilizer pridopidine on motor symptoms in Huntington’s disease: a meta-analysis. Clin Genet 80:48 (abstract 211)
Li Z, Huang M, Prus AJ, Dai J, Meltzer HY (2007) 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res 1134:70–78
Moro H, Sato H, Ida I, Oshima A, Sakurai N, Shihara N, Horikawa Y, Mikuni M (2007) Effects of SKF-38393, a dopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization and expression of immediate early gene arc in prefrontal cortex of rats. Pharmacol Biochem Behav 87:56–64
Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S (2006) The dopamine stabilizers (S)-(−)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(−)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318:810–818
Parfitt KD, Gratton A, Bickford-Wimer PC (1990) Electrophysiological effects of selective D1 and D2 dopamine receptor agonists in the medial prefrontal cortex of young and aged Fischer 344 rats. J Pharmacol Exp Ther 254:539–545
Pettersson F, Ponten H, Waters N, Waters S, Sonesson C (2010) Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). J Med Chem 53:2510–2520
Pirot S, Godbout R, Mantz J, Tassin JP, Glowinski J, Thierry AM (1992) Inhibitory effects of ventral tegmental area stimulation on the activity of prefrontal cortical neurons: evidence for the involvement of both dopaminergic and GABAergic components. Neuroscience 49:857–865
Ponten H, Kullingsjo J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, Waters S, Waters N (2010) In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol 644:88–95
Ponten H, Kullingsjo J, Sonesson C, Waters S, Waters N, Tedroff J (2013) The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model. Eur J Pharmacol 698:278–285
Povysheva NV, Zaitsev AV, Rotaru DC, Gonzalez-Burgos G, Lewis DA, Krimer LS (2008) Parvalbumin-positive basket interneurons in monkey and rat prefrontal cortex. J Neurophysiol 100:2348–2360
Puig MV, Artigas F, Celada P (2005) Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex 15:1–14
Pycock CJ, Carter CJ, Kerwin RW (1980) Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 34:91–99
Rezvani AH, Eddins D, Slade S, Hampton DS, Christopher NC, Petro A, Horton K, Johnson M, Levin ED (2008) Neonatal 6-hydroxydopamine lesions of the frontal cortex in rats: persisting effects on locomotor activity, learning and nicotine self-administration. Neuroscience 154:885–897
Robinson RG, Stitt TG (1981) Intracortical 6-hydroxydopamine induced an asymmetrical behavioral response in the rat. Brain Res 213:387–395
Sahlholm K, Arhem P, Fuxe K, Marcellino D (2013) The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the sigma-1 receptor. Mol Psychiatry 18:12–14
Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1–58
Sesack SR, Bunney BS (1989) Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study. J Pharmacol Exp Ther 248:1323–1333
Sidiropoulou K, Lu FM, Fowler MA, Xiao R, Phillips C, Ozkan ED, Zhu MX, White FJ, Cooper DC (2009) Dopamine modulates an mGluR5-mediated depolarization underlying prefrontal persistent activity. Nat Neurosci 12:190–199
Sonesson C, Andersson B, Waters S, Waters N, Tedroff J (2000) New modulators of dopamine neurotransmission, Patent application no. WO146145 A1
Steward O, Worley PF (2001) Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 30:227–240
Sullivan RM, Brake WG (2003) What the rodent prefrontal cortex can teach us about attention-deficit/hyperactivity disorder: the critical role of early developmental events on prefrontal function. Behav Brain Res 146:43–55
Tang TS, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signalling and striatal neurodegeneration in Huntington’s disease. J Neurosci 27:7899–7910
Tierney PL, Thierry AM, Glowinski J, Deniau JM, Gioanni Y (2008) Dopamine modulates temporal dynamics of feedforward inhibition in rat prefrontal cortex in vivo. Cereb Cortex 18:2251–2262
Tseng KY, O’Donnell P (2007) Dopamine modulation of prefrontal cortical interneurons changes during adolescence. Cereb Cortex 17:1235–1240
Wang J, O’Donnell P (2001) D(1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 11:452–462
Wang Y, Liu J, Gui ZH, Ali U, Fan LL, Hou C, Wang T, Chen L, Li Q (2011) Alpha2-Adrenoceptor regulates the spontaneous and the GABA/glutamate modulated firing activity of the rat medial prefrontal cortex pyramidal neurons. Neuroscience 182:193–202
Waters D, Waters S, Pettersson F, Dyhring T, Sonesson C, Tedroff J, Waters N, Pontén H. 76 (Suppl 1), 74 (Abstract D10 (2009) Pharmacology of the dopaminergic stabilizer pridopidine (ACR16). Clin. Genet 76 (Suppl 1):74
Yamamura S, Ohoyama K, Hamaguchi T, Nakagawa M, Suzuki D, Matsumoto T, Motomura E, Tanii H, Shiroyama T, Okada M (2009) Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. Br J Pharmacol 157:656–665
Acknowledgments
This work was supported by NeuroSearch Sweden. The authors thanks Mrs Ayah Siddiqi and Mr Mathieu Di Miceli (De MontfortUniversity) for editing support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gronier, B., Waters, S. & Ponten, H. The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex. J Neural Transm 120, 1281–1294 (2013). https://doi.org/10.1007/s00702-013-1002-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-013-1002-4